Editorial Comment to Longitudinal Changes in Overactive Bladder Symptoms After Prostatic Urethral Lift for Benign Prostatic Hyperplasia: A Japanese Single‐Center Prospective Study

The prospective, single‐center study by the authors provides critical real‐world longitudinal evidence regarding overactive bladder (OAB) symptoms after a prostatic urethral lift (PUL) using the UroLift system [1]. This paper arrives at a pivotal moment for The Japanese Urological Association. On April 9, 2026, the UroLift System Appropriate Use Guidance (2nd edition) in Japan was officially issued, signaling shifting indications and an expected expansion of the eligible patient population across Japan.

The indications and clinical practice patterns for PUL vary significantly between Western nations and Japan due to distinct social determinants, including regulatory frameworks, insurance reimbursement policies, and healthcare‐delivery models. While Western clinical trials often evaluate PUL in younger, lower‐risk cohorts, the Japanese clinical landscape frequently positions PUL for elderly patients with significant comorbidities who are unfit for more invasive conventional tissue‐ablative surgeries. The peer‐review process of this manuscript highly illuminates this unique Japanese context: the enrolled 140‐patient cohort carried a remarkably high burden of comorbidities, including hypertension (67.9%), cardiovascular disease (24.3%), and cognitive deterioration (31.4%), with 19.3% requiring antiplatelet or anticoagulant therapies.

Although the overall effect size was naturally attenuated by the real‐world consecutive inclusion of mild cases, a subgroup analysis confirmed that patients with clinically relevant baseline OAB achieved more pronounced, significant improvements. Furthermore, the durability and reliability of the OAB Symptom Score (OABSS) improvement were thoroughly validated through robust sensitivity analyses excluding patients with preoperative catheterization or those who resumed or initiated OAB/BPH medications postoperatively.

From a physiological perspective, storage symptom recovery is generally expected to follow the relief of bladder outlet obstruction and subsequent detrusor normalization. However, the authors observed early improvements within the first 3 months, closely aligning with changes in the IPSS storage subscore. This rapid temporal pattern suggests an “association” involving multiple early post‐procedural factors (such as reduced outlet resistance) rather than a single direct causal mechanism, a scientific nuance rightly clarified during the review.

When positioning PUL among contemporary minimally invasive surgical therapies (MIST)—such as water‐vapor thermal therapy (Rezum), which also reportedly reduces total OABSS from 6.1 to 3.9 at 6 months in Japanese real‐world data—the ideal candidate for PUL represents a specific clinical phenotype. Based on landmark data from the L.I.F.T. Study [2] and the MedLift Study [3] for obstructive median lobes, PUL is exceptionally well‐suited for patients with lateral‐lobe predominant obstruction, moderate‐to‐severe LUTS refractory to medical therapy, and a strong desire to preserve sexual and ejaculatory functions, or high‐risk elderly individuals. Although single‐center limitations, a 6‐month follow‐up, and the lack of urodynamic data restrict direct mechanistic causal inferences, this study provides exceptionally granular insights through item‐level OABSS analysis and responder classifications, successfully bridging the gap between global landmark trials and Japan's evolving domestic guidance.

Author Contributions

The author takes full responsibility for this article.

Conflicts of Interest

The author declares no conflicts of interest.

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.